CN107164325B - The preparation method and kit of the oligodendroglia in the source MSCs - Google Patents
The preparation method and kit of the oligodendroglia in the source MSCs Download PDFInfo
- Publication number
- CN107164325B CN107164325B CN201710508337.7A CN201710508337A CN107164325B CN 107164325 B CN107164325 B CN 107164325B CN 201710508337 A CN201710508337 A CN 201710508337A CN 107164325 B CN107164325 B CN 107164325B
- Authority
- CN
- China
- Prior art keywords
- opcs
- culture
- additive
- cell
- mscs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1361—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from dental pulp or dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1376—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from mesenchymal stem cells derived from hair follicles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a kind of oligodendroglia reagent preparation boxes in source MSCs, including OPCs serum-free basal medium, OPCs culture additive 1, OPCs culture additive 2 and OPCs culture surface coating buffer, wherein, the OPCs serum-free basal medium is to contain B27, N2, L-Glutamine, 1,25- dihydroxyvitamin D3, triiodothyronine, the DMEM/F12 culture medium of people's epiphysin;The OPCs culture additive 1 is the DMEM/F12 culture medium containing recombination human basic fibroblast growth factor, recombinant human epidermal growth factor;The OPCs culture additive 2 is the DMEM/F12 culture medium containing recombination human platelet derived growth factor AA, recombinant human nerve trophic factors 3;The OPCs culture surface coating buffer is the DMEM/F12 culture medium containing recombined human Laminin lens, recombined human vitronectin.
Description
Technical field
The present invention relates to cell preparation techniques field, it particularly relates to a kind of oligodendroglia in the source MSCs
Preparation method and kit.
Background technique
A variety of neurodegenerative diseases such as multiple sclerosis, leukaemia, malnutrition and central lesion
Deng that all myelin can be caused to lose, lack effective treatment means at present.Oligodendrocyte precursor cells (oligodendrocyte
Precursor cells, OPCs) differentiation generation oligodendroglia forms sheath structure, exception in central nervous system
It will lead to demyelinating disease of central nervous system change, then lead to neure damage and mental disorder, be important therapy target.
Oligodendrocyte precursor cells replacement therapy or Regeneration and Repair treatment are the aixs cylinders for maintaining and repairing damage, rebuild aixs cylinder electrical conduction function
The latest developments and most promising treatment means of energy.
The preparation of oligodendroglia in the prior art using embryonic stem cell (embryonic stem cells,
ESCs), the acquisition of (induced pluripotent stem cells, iPSCs) vitro differentiation is induced multi-potent stem cell.ESCs comes
The oligodendroglia cell preparation in source is related to serious ethics problem and in vivo the bad clinical risk of transplanting tumorigenesis,
The oligodendroglia preparation in the source iPSCs is related to foreign gene transfection and more serious internal the serious of transplanting oncogenicity faces
Bed risk.And ESCs or iPSCs Differentiation Induction in vitro prepares OPCs complex process, it is right using animal source components such as serum
The OPCs quality of the pharmaceutical preparations and clinical safety generate unpredictable influence, while limiting OPCs preparation yield, affect clinic
Research and industrialization Transformation Potential.
For the problems in the relevant technologies, currently no effective solution has been proposed.
Summary of the invention
For above-mentioned technical problem in the related technology, the present invention proposes a kind of system of the oligodendroglia in source MSCs
Preparation Method and kit had both avoided the oligodendroglia cell preparation using the source ESCs and the serious ethics that generates
Problem and in vivo the bad clinical risk of transplanting tumorigenesis also avoid generating using the oligodendroglia preparation in the source iPSCs
Foreign gene transfection and more serious internal transplanting oncogenicity bad clinical risk, easy to operate, OPCs high income, without dynamic
Material resource ingredient.
To realize the above-mentioned technical purpose, the technical scheme of the present invention is realized as follows:
A kind of oligodendroglia reagent preparation box in the source MSCs, including OPCs serum-free basal medium, OPCs training
Support additive 1, OPCs culture additive 2 and OPCs culture surface coating buffer, wherein
The OPCs serum-free basal medium is to contain B27, N2, L-Glutamine, 1,25- dihydroxyvitamin D3, three
Iodine desiodothyroxine, the DMEM/F12 culture medium of people's epiphysin;
The OPCs culture additive 1 is to grow containing recombination human basic fibroblast growth factor, recombinant human epidermal
The DMEM/F12 culture medium of the factor;
OPCs culture additive 2 be containing recombination human platelet derived growth factor AA, recombinant human nerve nutrition because
The DMEM/F12 culture medium of son 3;
The OPCs culture surface coating buffer is the DMEM/F12 containing recombined human Laminin lens, recombined human vitronectin
Culture medium.
Further,
The OPCs serum-free basal medium contains 1 × B27,1 × N2,2mM L-Glutamine, 1uM 1,25- dihydroxy
Vitamine D3,40ng/mL triiodothyronine, 0.5ug/mL people's epiphysin;
OPCs culture additive 1 be containing 1 ug/mL recombination human basic fibroblast growth factor, 1 ug/
The DMEM/F12 of mL recombinant human epidermal growth factor;
The OPCs culture additive 2 is to recombinate containing 1 ug recombination human platelet derived growth factor AA, 100ng/mL
The DMEM/F12 of people's neurotrophin 3;
The OPCs culture surface coating buffer is to contain 100ng/mL recombined human Laminin lens, 100ng/mL recombined human glass
The even DMEM/F12 of albumen.
According to another aspect of the present invention, a kind of oligodendroglia preparation method in source MSCs is provided, including such as
Lower step:
S1. it is coated with culture surface 1 hour with OPCs culture surface coating buffer room temperature, inhales and abandon coating buffer, rinse postposition through PBS
It saves and is no more than 1 week in 4 DEG C;
The MSCs in S2.P2 generation presses 6000/cm2Inoculation is cultivated with the MSCs containing 10% non-animal derived ingredient serum replacement
Base culture converges to 60-70%;
S3. the OPCs serum-free basal medium of the culture additive 1 containing OPCs is changed, culture to 80-90% converges, with pancreas egg
White enzyme solutions digestion harvest cell, is denoted as neural epithelium pre-induced cell;
S4. nerve is resuspended with the OPCs serum-free basal medium for cultivating additive 1 and OPCs culture additive 2 containing OPCs
Epithelium pre-induced cell, adjustment cell density to 1.5 × 104/cm2, it is seeded to by the coated culture of OPCs culture surface coating buffer
Surface, passage when culture converges to 60-80%, is denoted as P0 for OPCs.
Further,
The OPCs culture surface coating buffer is the OPCs culture surface coating buffer that 10 times are diluted through DMEM/F12;
OPCs culture 1 content of additive is 2% in the OPCs serum-free basal medium of the culture additive 1 containing OPCs;
It is described to cultivate OPCs training in the OPCs serum-free basal medium of additive 1 and OPCs culture additive 2 containing OPCs
It is 2% that the content for supporting additive 1, which is the content that 2%, OPCs cultivates additive 2,.
It further, further include following steps after the step S4: by P0 for OPCs routinely attached cell propagating method
Passage harvests P2 for cell.
Further, the inoculum density in the conventional attached cell propagating method succeeding generations is 1.5 × 104/cm2, training
The system of supporting is that the OPCs serum-free basal medium of additive 1 and 1% OPCs culture additive 2 is cultivated containing 1%OPCs;Cultivate table
Face is through the coated culture surface of OPCs culture surface coating buffer.
Further, the MSCs derives from people's umbilical cord, amnion, amniotic fluid, placenta, Cord blood, palace film, dental pulp, marrow, skin
Skin, tendon, skeletal muscle.
Beneficial effects of the present invention: the present invention provides the methods for preparing oligodendroglia as source using MSCs, and mention
A kind of kit that oligodendroglia is prepared using MSCs as source is supplied.MSCs is tissue-derived the most abundant adult stem cell
One of, oligodendroglia, which is prepared, using MSCs had both avoided the oligodendroglia cell preparation using the source ESCs and generate
Serious ethics problem and in vivo transplanting tumorigenesis bad clinical risk, also avoid using the source iPSCs less dash forward glue
The bad clinical risk of foreign gene transfection and more serious internal transplanting oncogenicity that cell plastid preparation generates, and operate letter
It is single, OPCs high income, non-animal derived ingredient.
Detailed description of the invention
Fig. 1 is cellular morphology figure of the P2 for MSCs;
Fig. 2 is P2 for MSCs cell expression nestin aspect graph;
Fig. 3 is P2 for MSCs cell expression A2B5 aspect graph;
Fig. 4 is neural epithelium pre-induced cellular morphology figure;
Fig. 5 is neural epithelium pre-induced cell expression nestin aspect graph;
Fig. 6 is neural epithelium pre-induced cell expression A2B5 aspect graph;
Fig. 7 is cellular morphology figure of the P0 for OPCs;
Fig. 8 is P0 for OPCs cell expression nestin aspect graph;
Fig. 9 is P0 for OPCs cell expression A2B5 aspect graph;
Figure 10 is cellular morphology figure of the P2 for OPCs;
Figure 11 is P2 for OPCs cell expression nestin aspect graph;
Figure 12 is P2 for OPCs cell expression A2B5 aspect graph;
Figure 13 is the statistical chart of the expression of different cultivation stage cell sign albumen;
Figure 14 is different cultivation stage cell yield statistical charts;
Figure 15 is oligodendroglia aspect graph;
Figure 16 is oligodendroglia expression nestin aspect graph;
Figure 17 is oligodendroglia expression A2B5 aspect graph;
Figure 18 is oligodendroglia expression MBP aspect graph.
Specific embodiment
Below in conjunction with specific embodiment, technical scheme in the embodiment of the invention is clearly and completely described.It is real
Apply various reagents used in example, machinery is commercially obtained without specified otherwise.
Firstly, to the factory of various products specifically used in the English name and embodiment occurred in the application
Family, article No. are briefly described.
OPCs: oligodendrocyte precursor cells, oligodendrocyte precursor cells.
ESCs: embryonic stem cell, embryonic stem cells.
MSCs: mesenchyma stromal cells, mesenchymal stroma cells.
DMEM/F12: being a kind of cell culture medium, and DMEM/F12 article No. used in embodiment is 12400-024, raw
Producing producer is GIBCO.
B27: human leucocyte antigen (HLA).
N2: being a kind of cell culture additive, N2 article No. used in embodiment is 17502-048, and manufacturer is
GIBCO。
PBS: phosphate buffer.
Non-animal derived ingredient serum replacement: non-animal derived ingredient serum replacement article No. used in embodiment is
C08003C, manufacturer are Stemboscience.
0.25% trypsin solution: 0.25% trypsin solution article No. is T6424-1VL used in embodiment, at
Producing producer is Biological industries.
Aprotinin solution: Aprotinin solution article No. is A1250000 used in embodiment, is Sigma at producer is produced.
FBS: fetal calf serum, article No. 04-400-1A, manufacturer BI.
T3: triiodothyronine, article No. 709611, manufacturer Sigma-Aldrich.
Sonic hedgehog: Sonic hedgehog, sonic hedgehog article No. used in embodiment is SRP3156,
Manufacturer is Sigma.
Noggin: noggin, Noggin article No. used in embodiment is H6416, and manufacturer is Sigma.
Double butyryl c-AMP: double butyryl c-AMP article No.s used in embodiment are D0627, and manufacturer is Sigma.
IGF-1: insulin-like growth factor 1, article No. cyt-216, manufacturer Prospec-Tany.
NT3: neurotrophin 3, article No. cyt-257, manufacturer Prospec-Tany.
Embodiment one: the composition of kit
The oligodendroglia reagent preparation box in the source MSCs includes OPCs serum-free basal medium (OBM), OPCs training
Support additive 1(OS1), OPCs cultivate additive 2(OS2) and OPCs culture surface coating buffer (OCB).
Wherein, OPCs serum-free basal medium (OBM) is the DMEM/F12 culture medium comprising following substance:
1 × B27,
1 × N2,
2mM L-Glutamine,
1uM 1,25- dihydroxyvitamin D3 (1,25 (OH) 2D3),
40ng/mL triiodothyronine (3,3', 5-tri-iodo-thyronine, T3),
0.5ug/mL people's epiphysin (Melatonin).
OPCs cultivates additive 1(OS1) be the DMEM/F12 culture medium comprising following substance:
1 ug/mL recombination human basic fibroblast growth factor (rh b-FGF),
1 ug/mL recombinant human epidermal growth factor (rh EGF).
OPCs cultivates additive 2(OS2) be the DMEM/F12 culture medium comprising following substance:
1 ug recombination human platelet derived growth factor AA(rh PDGF-AA),
100ng/mL recombinant human nerve trophic factors 3(rh NT-3).
OPCs culture surface coating buffer (OCB) is the DMEM/F12 culture medium comprising following substance:
100ng/mL recombined human Laminin lens (liminin, LN),
100ng/mL recombined human vitronectin (vitronectin (VN)).
The preparation of embodiment two: OPCs
The reagent that the preparation of OPCs uses, except PBS, digestive juice, freeze protection liquid in addition to, be described in embodiment one
The oligodendroglia reagent preparation box in the source MSCs provides.
S1. OS1, OS2, OCB that -20 DEG C or less freeze are thawed overnight under the conditions of 4 DEG C spare;
S2. the OCB in kit is diluted to through DMEM/F12 with 10 × OCB(final concentration of 10%) by every milliliter of packet
By 35cm2Culture surface room temperature is coated with culture surface 1 hour, is inhaled and is abandoned coating buffer, is rinsed 3 times with 2-8 DEG C of PBS, is placed in 4 DEG C of preservations
No more than 1 week;
S3. people's umbilical cord, amnion, amniotic fluid, placenta, Cord blood, palace film, dental pulp, marrow, skin, tendon, skeletal muscle etc. are organized
The P2 in source is for MSCs, by 6000/cm2Inoculation, to contain the MSCs culture medium culture of 10% non-animal derived ingredient serum replacement
Converge to 60-70%;
S4. the OBM culture medium containing 2%OS1 is changed, culture to 80-90% converges, and is digested and is harvested with 0.25% trypsin solution
Cell is denoted as neural epithelium pre-induced cell;
S5. neural epithelium pre-induced cell is resuspended containing the OBM culture medium of 2%OS1 and 2% OS2, adjustment cell density is extremely
1.5×104/cm2, passage when being seeded to OCB coated culture surface culture 60-80% converging in 4-6 days is denoted as P0 for OPCs;
For OPCs, routinely attached cell propagating method passes on S6.P0, digestive juice AccutaseTMDigestive juice (article No.
40506ES60, manufacturer Innovative Cell Technologies, Inc.), inoculum density is 1.5 × 104/cm2,
Cultivating system is the OBM culture medium containing 1%OS1 and 1% OS2;Culture surface is the coated culture surface of OCB;
S7. harvest P2 can directly prepare preparation for cell, can also be with cryopreservation, and freezing protection liquid using article No. is
CELLBANKER-II, manufacturer freeze protection liquid for ZENOAQ's, and freeze-stored cell density is 2 × 106/mL。
Embodiment three: the OPCs external preparation in the source umbilical cord MSCs
3.1 umbilical cord MSCs are separately cultured
With tissue block method originally culture umbilical cord MSCs, cultivating system is MSCs culture medium, that is, contains 10% non-animal derived component blood
The DMEM/F12 culture medium of clear substitute, when culture was to 12 days, gently shake culture bottle, suspension remnant tissue block, careful inhale are abandoned
Culture supernatant, PBS are washed culture surface 1 time, and 0.25% trypsin solution is added, and room temperature digests 5 minutes, and 1mL Aprotinin is added
Solution terminates digestion;400g is centrifuged 5min, abandons supernatant, harvests sediment;With PBS washing 2 times, it is sieved through with 100um Nylon cell
Filtrate is collected in filter;400g is centrifuged 5min, abandons supernatant, harvests sedimentation cell, is denoted as P0 for MSCs;P0 is cultivated for MSCs with MSCs
Base weight is outstanding, and adjustment cell density is 6000/cm2, it is seeded to 175cm2Tissue culture flasks (EasyFlask, NUNC), culture to 70-
80% harvests P1 for MSCs when converging;By 6000/cm of cell density2Continue to pass on, harvests P2 for MSCs.
The source 3.2MSCs OPCs preparation
P2 is resuspended for the MSCs in umbilical cord source, by 6000/cm with MSCs culture medium2It is seeded to 175cm2Tissue culture flasks,
Culture converges to 60-70%, changes the OBM culture medium containing 2%OS1, and culture to 80-90% converges, and inhales and abandons culture supernatant, PBS washing training
It supports surface 1 time, 0.25% trypsin solution is added, room temperature digests 5 minutes, and 1mL Aprotinin solution is added and terminates digestion;400g
Centrifugation, 5min abandon supernatant, harvest sedimentation cell, are denoted as neural epithelium pre-induced cell;
Neural epithelium pre-induced cell is resuspended containing the OBM culture medium of 2%OS1 and 2% OS2, by 1.5 × 104/cm2Inoculation
To the coated 175cm of OCB2Tissue culture flasks change liquid every other day, when 60-80% converges, inhale and abandon culture supernatant, PBS washing culture table
Accutase is added in face 1 timeTMDigestive juice (article No. 40506ES60, manufacturer Innovative Cell Technologies,
Inc.) 5mL, room temperature digest 5 minutes, and 1mL Aprotinin solution is added and terminates digestion;400g is centrifuged 5min, abandons supernatant, harvest precipitating
Cell is denoted as P0 for OPCs;
P0 is resuspended for OPCs, by 1.5 × 10 containing the OBM culture medium of 2%OS1 and 2% OS24/cm2It is coated to be seeded to OCB
175cm2Tissue culture flasks, harvest when culture converges to 60-80%, are denoted as P1 for OPCs;P1 continues secondary culture to P2 for OPCs
Generation, harvest.
Example IV: P2 is detected for the OPCs differentiation potential in the source MSCs
4.1 oligodendrocyte differentiation cultures
By 5 × 104/ mL is inoculated with P2 and cultivates for OPCs in the coated 24 hole tissue culturing plate of OCB, and every two and half amount changes liquid,
Row histology at the 8th day.Oligodendrocyte differentiation culture medium is the DMEM/F12 culture medium containing following ingredient:
2% non-animal derived ingredient serum replacement,
2%FBS,
1 × N2,
40ng/mL T3,
100ng/mL sonic hedgehog,
100 ng/ml Noggin,
10 μM of double butyryl,
100 ng/ml IGF-1,
10ng/NT3。
4.2MSCs, the general Biological Detection of neural epithelium pre-induced cell, OPCs, oligodendroglia
4.2.1 immunohistology detects
When attached cell immunohistology detects, inhales and abandon culture medium, it is solid with 4% paraformaldehyde (PFA) with PBS rinsing 2 times
Determine cell 10 minutes, with PBS rinsing 2 times, primary antibody is added dropwise, 4 DEG C overnight;PBS is washed 2 times, and FITC is added dropwise and marks secondary antibody, room temperature is incubated
It educates 1 hour;PBS is rinsed 2 times, and 1 μ g/ ml 4', 6- diamidino -2-phenylindone (DAPI) is added dropwise, and is incubated for 5 minutes, PBS rinsing
2 times, microscopy.
Immunohistochemical detection includes: using antibody
Mouse anti-nestin[clone 10C2 (1:400), manufacturer Millipore];
Mouse anti-A2B5[clone 105 (1:500), manufacturer R&D Systems];
Rabbit anti-MBP [(1:200), manufacturer Sigma-Aldrich];
FITC marks secondary antibody: the anti-mouse IgG (1:200) of monkey and goat anti-rabbit igg (1:200) (manufacturer Life
Technologies).
4.2.2 cell yield counts
With cell imaging system (Cytell Cell Imaging System, GE Healthcare) row viable count
With immunohistology dyeing counting, comprising: P2 is for MSCs, nestin+DAPI+ neural epithelium pre-induced cell quantity, nestin+
The P0 of DAPI+, A2B5+DAPI+ are for OPCs and P2 for OPCs quantity, and the P2 of MBP+, DAPI+ are for OPCs and oligodendroglia number
Amount.
Statistical analysis carries out statistical procedures using SPSS17.0.Data with± S indicates that mean value compares using independent
Sample t-test, P < 0.05 are statistically significant.
Embodiment five: statistical result
5.1 neural epithelium pre-induced cell culture
The expression statistical result of different cultivation stage cell sign albumen is as shown in figure 13.
As shown in Fig. 1 ~ 3,
P2 extends for MSCs with incubation time to be grown in typical circinate, and most cells are spindle shape, and minority is triangle
Shape, polygonal (Fig. 1);
11.87 ± 1.15% cell expresses nestin(Fig. 2);
7.84 ± 0.56% cell expresses A2B5(Fig. 3);
As shown in Fig. 4 ~ 6,
After the OBM culture medium culture containing 2%OS1, cell is gradually parallel to each other, and retracts cytoplasm, forms obvious elongate
Cell body (Fig. 4);
95.84 ± 8.61% cell expresses nestin(Fig. 5);
21.84 ± 5.56% cell expresses A2B5(Fig. 6).
5.2P0 being cultivated for OPCs
As shown in Fig. 7 ~ 9
With OBM culture medium culture neural epithelium pre-induced cell 4-6 days containing 2%OS1 and 2% OS2, part attached cell
Obtain ambipolar OPCs form (Fig. 7);
45.21 ± 4.66% cell expresses nestin(Fig. 8);
46.22 ± 7.39% cell expresses A2B5(Fig. 9).
5.3P2 being cultivated for OPCs
With the OBM culture medium squamous subculture P0 containing 1%OS1 and 1% OS2 for OPCs to P2 generation, most cells shows are bipolar out
Property or three polarity, a few cell show multipolarity form (Figure 10);
41.83 ± 3.91% cell expresses nestin(Figure 11);
92.09 ± 11.43% cell expresses A2B5(Figure 12).
5.4OPCs cell yield
Different cultivation stage cell yield statistical results are as shown in figure 14.
1.05×106P2 presses 6000/cm for MSCs2It is inoculated into 175cm2In tissue culture flasks (Easyflask, NUNC),
Obtain 5.74 ± 1.48 × 106Neural epithelium pre-induced cell;
Neural epithelium pre-induced cell about presses 1.5 × 104/cm2It is seeded to coated 2 175cm of OCB2Tissue culture flasks
In (Easyflask, NUNC), 15.66 ± 3.39 × 10 are obtained6P0 is for OPCs;
P0 about presses 1.5 × 10 for OPCs4/cm2It is seeded to coated 6 175cm of OCB2Tissue culture flasks (Easyflask,
NUNC in), 46.51 ± 8.82 × 10 are obtained6P1 then about presses 1.5 × 10 for OPCs4/cm2It is seeded to OCB coated 18
175cm2In tissue culture flasks (Easyflask, NUNC), 139.89 ± 36.22 × 10 are obtained6P2 is for OPCs.
P2 presses 5 × 10 for OPCs4/ mL is inoculated in the coated 24 hole tissue culturing plate of OCB and cultivates 8 days, induces oligodendroglia
Cell differentiation.The result shows that culture starts on the 4th day, cell stops proliferation, a large amount of cell deaths, until at the 8th day, Average Survival
Cell number is 2.24 ± 0.88 × 104/ hole, and all cell differentiations are at typical oligodendroglia sample form (Figure 15).
Immunohistochemical detection the result shows that, 2.83 ± 0.52% survivaling cells express nestin(Figure 16), 9.95 ±
2.22% survivaling cell expresses A2B5(Figure 17), and 98.31 ± 11.42% survivaling cells express MBP(Figure 18).
Embodiment six: interpretation of result
Mammalian central nervous system damage, aixs cylinder demyelinate and oligodendroglia cell death cause myelin to damage
It is the major reason for causing Nerve conduction to lose that caused action potential, which propagates interruption, after wound, missing, and damage is thin after occurring
Born of the same parents, which are difficult to regenerate, hinders neurological functional recovery.The past studies have shown that cell transplantation, especially neural precursor transplanting lure
The raw myelin of artificial delivery can promote aixs cylinder Remyelination, restore complete action potential conduction and nervous function.Embryonic stem cell, nerve
A variety of embryos such as stem cell, adult stem cell can be divided into OPCs, and the cell therapy for myelin loss provides potential cell
Source.But the ethical hindrances of embryonic stem cell clinical application and in vivo transplanting oncogenicity are as derived from embryonic stem cells
One of the biggest obstacle of OPCs treatment demyelinating disease.Postnatal adult acquisition neural stem cell is extremely difficult, and cell concentration is difficult
To guarantee, therefore adult neural stem cell, mostly from aborted fetus, ethical hindrances are bigger.So more researchs are focused on into
The OPCs that body multipotential stem cell is external evoked, amplification generates.
MSCs is the multipotential stem cell for being present in Various Tissues, has triploblastica differentiation potential.Except adult bone marrow, fat,
Outside the tissues such as skin, can it be separated in the tissue such as fetus at perinatal stage adjunct, including umbilical cord, amnion, amniotic fluid, placenta, Cord blood
A large amount of MSCs out.Wherein the MSCs in umbilical cord source is easiest to pilot scale culture and amplification, and cell uniformity is good, and have at
Bone, at fat, at cartilage, at endothelial progenitor cells, at differentiation potentials such as neural stem cell, immunogenicity is low, not bright after transplanting
Aobvious adverse reaction and oncogenicity.Currently, the country has been set up multiple libraries MSCs, thus MSCs become except candidate stem cell it
Outside, it is most suitable for the seed cell for cell therapy, the OPCs preparation system in the exploitation source MSCs is that OPCs transplantation treatment takes off marrow
Most important technological problems in sheath disease Industrialization Way.The research of the past focuses mostly on dry thin with embryonic stem cell, induced multi-potent
The OPCs induction system of born of the same parents, i.e., using " embryoid body culture-nerve ball-OPCs induction differentiation " three step preparation systems, in recent years
Come, there is team to prepare the OPCs in the source MSCs using this system, but because of complex process, is difficult to meet the OPCs mark in the source MSCs
Standardization, prepare with scale.
Based on the above situation, applicant develops a kind of kit, prepared by the OPCs industrialization for the source MSCs, is not necessarily to
By nerve ball cultivation stage, routinely pass on, simple process, and this kit without the animal sources such as any serum at
Point, meet requirement of the clinical research to culture medium.Cell preparation is used for clinical research and clinical application, and cell quantity not only needs
Meet the requirement of clinical dosage, it is also necessary to meet the requirement of quality control.The past studies have shown that in addition to embryonic stem cell energy
A large amount of induction differentiation generate neural stem cell, then differentiation is induced to generate outside OPCs, are difficult to obtain by nerve ball culture and induction
The OPCs that quantity is enough, A2B5 positive rate is high.The P2 in the source MSCs is prepared for OPCs, in addition to A2B5 is expressed using this kit
Rate is up to 92.09 ± 11.43%(attached drawing 13), external oligodendroglia induction yield is up to 44.04%(attached drawing 14) outside, it compares
In P2 for MSCs, expands multiplying power and be up to 133.23 times (attached drawings 14).By taking this laboratory prepares P2 for the MSCs in umbilical cord source as an example,
The umbilical cord of a piece 10cm, P2 is for MSCs yield average out to 1.34 ± 1.10 × 109, external preparation should can harvest 1.79 × 1011
P2 fully meets the industrialization preparation demand for establishing the library OPCs for OPCs.Therefore, this kit be it is a it is easy to use, without blood
The animal source components such as clear, the efficient kits for preparing A2B5+OPCs.
Claims (4)
1. a kind of oligodendroglia preparation method in the source MSCs, which comprises the steps of:
S1. it is coated with culture surface 1 hour, is inhaled with the OPCs culture surface coating buffer room temperature for diluting 10 times through DMEM/F12 culture medium
Coating buffer is abandoned, 4 DEG C is placed on through PBS rinsing and saves no more than 1 week;
The MSCs in S2.P2 generation presses 6000/cm2Inoculation is trained with the MSCs culture medium containing 10% non-animal derived ingredient serum replacement
It supports to 60-70% and converges;
S3. the OPCs serum-free basal medium of the culture additive 1 containing OPCs is changed, culture converges to 80-90%, uses trypsase
Solution digestion harvests cell, is denoted as neural epithelium pre-induced cell;
S4. neural epithelium is resuspended with the OPCs serum-free basal medium for cultivating additive 1 and OPCs culture additive 2 containing OPCs
Pre-induced cell, adjustment cell density to 1.5 × 104/cm2, it is seeded to by the coated culture table of OPCs culture surface coating buffer
Face, passage when culture converges to 60-80%, is denoted as P0 for OPCs;
Wherein, the OPCs serum-free basal medium is to contain 1 × B27,1 × N2,2mM L-Glutamine, 1uM 1,25-
Dihydroxyvitamin D3,40ng/mL triiodothyronine, the DMEM/F12 culture medium of 0.5ug/mL people's epiphysin;
The OPCs culture additive 1 is containing 1 ug/mL recombination human basic fibroblast growth factor, 1 ug/mL weight
The DMEM/F12 culture medium of group hEGF;
The OPCs culture additive 2 is containing 1 ug recombination human platelet derived growth factor AA, 100ng/mL recombined human mind
DMEM/F12 culture medium through trophic factors 3;
The OPCs culture surface coating buffer is to connect egg containing 100ng/mL recombined human Laminin lens, 100ng/mL recombined human glass
White DMEM/F12 culture medium;
OPCs culture 1 content of additive is 2% in the OPCs serum-free basal medium of the culture additive 1 containing OPCs;
OPCs culture adds in the OPCs serum-free basal medium containing OPCs culture additive 1 and OPCs culture additive 2
It is 2% that the content for adding agent 1, which is the content that 2%, OPCs cultivates additive 2,.
2. a kind of oligodendroglia preparation method in source MSCs according to claim 1, which is characterized in that the step
Further include following steps after rapid S4: by P0, for OPCs, routinely attached cell propagating method is passed on, and harvests P2 for cell.
3. a kind of oligodendroglia preparation method in source MSCs according to claim 2, which is characterized in that described normal
Advising the inoculum density in attached cell propagating method succeeding generations is 1.5 × 104/cm2, cultivating system is that the culture containing 1%OPCs adds
Agent 1 and 1% OPCs is added to cultivate the OPCs serum-free basal medium of additive 2;Culture surface is to be coated with through OPCs culture surface
The coated culture surface of liquid.
4. a kind of oligodendroglia preparation method in source MSCs according to claim 1, which is characterized in that described
MSCs derives from people's umbilical cord, amnion, amniotic fluid, placenta, Cord blood, palace film, dental pulp, marrow, skin, tendon, skeletal muscle.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710508337.7A CN107164325B (en) | 2017-06-28 | 2017-06-28 | The preparation method and kit of the oligodendroglia in the source MSCs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710508337.7A CN107164325B (en) | 2017-06-28 | 2017-06-28 | The preparation method and kit of the oligodendroglia in the source MSCs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107164325A CN107164325A (en) | 2017-09-15 |
CN107164325B true CN107164325B (en) | 2019-09-17 |
Family
ID=59826928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710508337.7A Active CN107164325B (en) | 2017-06-28 | 2017-06-28 | The preparation method and kit of the oligodendroglia in the source MSCs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107164325B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107988142A (en) * | 2017-11-07 | 2018-05-04 | 北京再生生物科技研究院有限公司 | One kind orientation EPC like cells, preparation method and applications |
CN108624560B (en) * | 2018-06-01 | 2022-04-08 | 南京艾尔普再生医学科技有限公司 | Differentiation culture medium and preparation method of oligodendrocyte precursor cells |
CN116144595A (en) * | 2023-03-07 | 2023-05-23 | 徐轶冰 | Method for promoting MSC to differentiate into oligodendrocyte precursor cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105200008A (en) * | 2015-10-23 | 2015-12-30 | 新乡医学院 | Stem Cell Medium |
-
2017
- 2017-06-28 CN CN201710508337.7A patent/CN107164325B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107164325A (en) | 2017-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103060264B (en) | Stem cell culture medium and application thereof and stem cell cultivation method | |
CN103243070B (en) | Stem cell medium and application thereof | |
US10370639B2 (en) | Method for preparing pluripotent stem cells | |
CN102899287B (en) | Method for inducing differentiation from mesenchymal stem cells to cartilage cells and application of mesenchymal stem cells in osteoarthritis | |
JP5700301B2 (en) | Method for inducing differentiation of neural crest cells from pluripotent stem cells | |
US20190177684A1 (en) | Stem Cells Derived from Pure Chorionic Trophoblast Layer and Cell Therapy Comprising Same | |
CN106479971A (en) | A kind of serum-free medium for cultivating mescenchymal stem cell and method | |
CN101748096A (en) | Sub totipotential stem cell and preparation method and application thereof | |
CN110396499A (en) | A method of inducing neural stem cells and its application | |
CN107254443B (en) | Induction medium and induction method for promoting differentiation of mesenchymal stem cells to neurons | |
CN104031882A (en) | Method for differentiating human neural stem cells into dopaminergic neuron by in-vitro directional induction | |
CN108570448B (en) | A kind of method that efficient hPSCs breaks up to MSCs | |
CN107164325B (en) | The preparation method and kit of the oligodendroglia in the source MSCs | |
CN104928247A (en) | Neural stem cell culture medium and neural stem cell adherent culture method | |
CN105331579A (en) | Separation and culture method and application of human testis mesenchymal stem cells | |
Dai et al. | The Human Skin‐Derived Precursors for Regenerative Medicine: Current State, Challenges, and Perspectives | |
Sauerzweig et al. | A population of serumdeprivation-induced bone marrow stem cells (SD-BMSC) expresses marker typical for embryonic and neural stem cells | |
JP2004511266A (en) | Therapeutic uses for mesenchymal stromal cells | |
CN104774808A (en) | Method for inducible differentiation of umbilical cord mesenchymal stem cells into gamma-aminobutyric acid-ergic neuron | |
WO2023221438A1 (en) | Method for promoting differentiation of ipsc into islet cell by means of regulating ngn3 expression | |
CN102021143A (en) | Pretreatment method for improving migration capability of mesenchymal stem cells | |
CN105087475B (en) | A kind of method that cell culture fluid and its application and induction dental pulp stem cell break up to neural-like cells | |
CN107384862B (en) | Preparation method and kit of Schwann cells derived from MSCs (mesenchymal stem cells) | |
Vasyliev et al. | Large-scale expansion and characterization of human adult neural crest-derived multipotent stem cells from hair follicle for regenerative medicine applications | |
CN101451123A (en) | Method for inducing human mesenchymal stem cells differentiation to oligoden drocyte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Ge Inventor after: Yuan Chunhui Inventor before: Zhang Hongdian Inventor before: Yuan Chunhui |
|
CB03 | Change of inventor or designer information |